Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases
Authors:
Preprint
Abstract
Deregulation of the cyclin-dependent kinases 4 and 6 (CDK4/6) is highly prevalent in cancer yet inhibitors against these kinases currently show use in restricted tumour contexts. The extent to which cancers depend on CDK4/6 and what may undermine such dependency is poorly understood. Here we report that signalling engaging the MET proto-oncogene receptor tyrosine kinase/focal adhesion kinase (FAK) axis leads to CDK4/6-independent CDK2-activation, involving as a critical mechanistic events loss of the CDK inhibitor p21 CIP1 and gain of its regulator, the ubiquitin ligase subunit SKP2. Combined inhibition of MET/FAK and CDK4/6 eliminates proliferation capacity of cancer cells in culture, and enhances tumour growth inhibition in vivo . Activation of the MET/FAK axis is known to arise through cancer extrinsic and intrinsic cues. Our work predicts that such cues support cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases and identifies MET/FAK as a tractable route to broaden the utility of CDK4/6 inhibitor-based therapies in the clinic.Keywords
All Related Versions
- Published version: Oncogene, 38 (30), 5905.
This publication has 52 references indexed in Scilit:
- A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancerCurrent Medical Research and Opinion, 2017
- Inhibitors of cyclin-dependent kinases as cancer therapeuticsPharmacology & Therapeutics, 2017
- The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination StrategiesTrends in Cancer, 2017
- Progress with palbociclib in breast cancer: latest evidence and clinical considerationsTherapeutic Advances in Medical Oncology, 2016
- Targeting CDK4/6 in patients with cancerCancer Treatment Reviews, 2016
- Targeting CDK4 and CDK6: From Discovery to TherapyCancer Discovery, 2016
- Treating cancer with selective CDK4/6 inhibitorsNature Reviews Clinical Oncology, 2016
- Signaling through cyclin D-dependent kinasesOncogene, 2013
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- An Integrated Genomic Analysis of Human Glioblastoma MultiformeScience, 2008